Clinical trials
Rejection clinical trials
Below are recruiting rejection clinical trials, each written for real people, not researchers. We’re tracking 102 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07053488RecruitingPhase 1/Phase 2
Gene-edited liver transplant to lower rejection risk
This trial tests a liver transplant using a donor organ that has been gene-edited to reduce the risk of rejection. It may help people who need a liver transplant and are not a perfect tissue match with their donor.
Beijing, ChangpingAges 16–85 - NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT06990711RecruitingPhase 1
Siltuximab for antibody-mediated rejection after lung transplant
This trial tests a drug called siltuximab to see if it can help treat a type of lung rejection called antibody-mediated rejection (AMR) in people who have had a lung transplant. You may be eligible if you are currently hospitalized for AMR and are already planning to receive standard treatments.
St Louis, MissouriAges 18 years+ - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT06824402Recruiting
Cryoprobe Biopsy for Chronic Rejection in Lung Transplant
This trial tests a new biopsy method called cryoprobe (using a cold probe) to better detect chronic rejection in lung transplant patients. It is for patients who already need a lung biopsy, either for routine monitoring or because of a concern.
Rochester, MinnesotaAges 18–99 - NCT06774365Recruiting
Heart imaging and blood tests for transplant rejection detection
This study uses advanced heart imaging and blood tests to detect a type of rejection that can happen after a heart transplant. It may help doctors diagnose antibody-mediated rejection earlier and more accurately.
Bari, BariAges 18 years+ - NCT04615221Recruiting
Study of immune rejection after uterine transplant
This study looks at why the body’s immune system may reject a transplanted uterus or a related surgery. Your results may help doctors understand rejection and improve care for future uterine transplants.
SuresnesAges 18–45 - NCT06351488Recruiting
Detecting kidney DNA to spot organ rejection early
This study looks for pieces of kidney DNA in the blood of people who have a kidney transplant and need a biopsy. The goal is to see if this test can help doctors know if the kidney is being rejected without needing a biopsy.
ParisAges 18 years+ - NCT05084768Recruiting
Test blood markers to predict kidney transplant rejection
This study looks at special blood tests to help predict when kidney transplant rejection might happen. If the markers work, they could help doctors catch rejection earlier and adjust treatment sooner.
Loma Linda, CaliforniaAges 18 years+ - NCT06948097RecruitingPhase 1
Testing fostamatinib for lung transplant patients with donor-specific antibodies
This trial tests a new medicine called fostamatinib for people who have had a lung transplant and have developed donor-specific antibodies (DSA) on their lung. The goal is to see if this medicine is safe and can help prevent the body from rejecting the new lung.
Stanford, CaliforniaAges 18–99 - NCT07875595Recruiting
Immune markers for predicting problems after liver transplant
This study looks at blood markers of the immune system to see if they can predict complications after a liver transplant. It aims to help doctors personalize care and catch problems early.
Pilar, Buenos AiresAges 18 years+ - NCT04526431Recruiting
Tacrolimus dose study in early kidney transplant patients
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
Grenoble, Auvergne-Rhône-AlpesAges 18 years+ - NCT05793203Recruiting
Tests noninvasive checks to spot liver transplant complications early
This study looks at how well noninvasive tests (tests that don’t require surgery or taking tissue) can detect complications after a liver transplant. It may help patients and teams find problems earlier using safer, easier monitoring.
RomeAges 18–75 - NCT05586906Recruiting
Breath test to detect lung transplant problems early
This trial looks at a simple, noninvasive breath test to spot early lung transplant dysfunction after a lung transplant. Because it focuses on testing after the transplant, it may help your care team catch issues earlier.
ZurichAges 18 years+ - NCT06557564Recruiting
Liver transplant biopsy study using TruGraf
This study uses a blood test called TruGraf to check for liver transplant problems. It may help diagnose issues without a biopsy.
Toronto, OntarioAges 18 years+ - NCT06025240Recruiting
Better antibody monitoring after kidney transplant
This study tests a new way to monitor harmful antibodies after a kidney transplant. It may help prevent transplant rejection over time.
Liverpool, MerseysideAges 18 years+ - NCT05936333Recruiting
Study why repeated pregnancy problems happen in some cases
This study looks at how the immune system may contribute to ongoing placenta inflammation in certain pregnancy histories. It may help researchers better understand causes behind pregnancy loss and related placental complications, using past placenta/tissue samples.
ClamartAges 18 years+ - NCT06676696RecruitingPhase 4
Stopping immunosuppression after failed kidney transplant
This study compares what happens when patients with a failed kidney transplant (still in the body) stop their immunosuppressant medicines at 6 months versus continuing them. The goal is to safely prevent your immune system from becoming too sensitive, which can make finding a new donor kidney harder.
BarcelonaAges 18 years+ - NCT05333367Recruiting
Study of how a light treatment causes immune cell death
This trial looks at how “extracorporeal photochemotherapy” (a light-based treatment done outside the body) works at the cellular level. It may help improve treatment and control for people dealing with immune reactions after transplant or certain blood/skin conditions.
BesançonAges 18–85 - NCT06717542Recruiting
Liver tissue analysis to predict transplant success
This study looks at liver tissue before transplantation to find ways to predict how well the transplant will work. It involves a special treatment called HOPE to help preserve the liver.
BolognaAges 18 years+ - NCT07539857RecruitingPhase 2
Belimumab to help highly sensitized kidney transplant candidates
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
LeidenAges 18 years+ - NCT07508787RecruitingPhase 2
Study comparing siplizumab to another drug for kidney transplant acceptance
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Sacramento, CaliforniaAges 18–70 - NCT06794970Recruiting
Tissue study for chronic kidney transplant rejection
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
Bologna, BOAges 18 years+ - NCT06795958Recruiting
Detecting heart rejection without a biopsy in children
This trial tests if a special MRI can detect early signs of heart rejection in children and young adults who have had a heart transplant. If successful, it might reduce the need for invasive biopsies.
BolognaAges Up to 18 years
Hear when a new Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for rejection?
- Yes. Clin2 currently lists 102 recruiting rejection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rejection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rejection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.